Browse by Publisher
Browse by Region

Industry Reports >> Pharmaceuticals and Healthcare

Browse the latest reports in the pharmaceuticals and healthcare industry below. You can sort your results by publication date, by price or alphabetically

Sort By:
Report Status:
26742 Report Results
Page 1 of 1070
Go To Page:
    
  Go

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Israel

$1,995.00
By:
, Published: Dec-2016

GlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Israel”. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Israel. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement la.....

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – South Africa

$1,995.00
By:
, Published: Dec-2016

GlobalData, the industry analysis specialist, has released its latest report: “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – South Africa”. The report is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in South Africa. It identifies the key trends in the country’s healthcare market and provides insights into its demographi.....

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – US

$1,995.00
By:
, Published: Dec-2016

GlobalData, the industry analysis specialist, has released its latest report: “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – US”. The report is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in the US. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory, a.....

Frontier Pharma: Type 2 Diabetes Mellitus – GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

$6,995.00
By:
, Published: Dec-2016

Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia (high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular, renal and neurodegenerative diseases.

Global prevalence of the disease has risen rapidly in the past several decades, primarily as a result of rising obesity, a major risk factor for T2DM. This has result.....

Diabetes & Obesity Drug Development Pipeline Review, 2016

$3,995.00
By:
, Published: Dec-2016

The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority.....

Ophthalmology Drug Development Pipeline Review, 2016

$3,995.00
By:
, Published: Dec-2016

Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, and particularly blindness, can arise. Although there are a number of treatments approved in ophthalmology, there are currently no curative therapies for any of these indications. In particular, there are strong unmet needs within age-related macular degeneration and glaucoma, which can lead to blindness.....

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q3 2016

$1,500.00
By:
, Published: Dec-2016

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q3 2016” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equi.....

PharmaPoint: Psoriatic Arthritis – Global Drug Forecast and Market Analysis to 2025

$10,995.00
By:
, Published: Dec-2016

Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially those of the lower extremities and distal joints of the fingers and toes as well as the back and sacroiliac joints of the pelvis. In approximately 80% of PsA patients, skin lesions of psoriasis (PsO), an immune-mediated skin disease, manifest prior to the development of PsA, typically by five to 10 years. PsA most commonly develops.....

EpiCast Report: Psoriatic Arthritis – Epidemiology Forecast to 2025

$3,995.00
By:
, Published: Dec-2016

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy that may be progressive in nature and can lead to severe joint damage and disability. The disease is considered to be rare in the general population, but PsA may affect up to 30% of persons with psoriasis (Ogdie and Gelfand, 2011; NPF, 2016).

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of PsA will increase from 1,044,022 cases in 2015 t.....

EpiCast Report: Hepatitis C Virus – Epidemiology Forecast to 2025

$3,995.00
By:
, Published: Dec-2016

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV can cause both acute and chronic hepatitis infection. According to the World Health Organization (WHO), an estimated 130–150 million individuals worldwide are affected with chronic HCV and about 500,000 people died of HCV-related conditions, including liver cirrhosis and hepatocellular carcinoma (HCC), in 2010 (Lozano et al., 2012; WHO, 2015).

In .....

EpiCast Report: Immune Thrombocytopenia (ITP) – Epidemiology Forecast to 2025

$3,995.00
By:
, Published: Dec-2016

Immune thrombocytopenia (ITP) is an autoimmune syndrome involving the antibody- and cell-mediated destruction of platelets and the suppression of platelet production; this increases an affected individual’s susceptibility to bleeding. More specifically, the destruction and suppression of platelets are due to B cell (and sometimes CD8+ T cell) autoimmune reactions directed against circulating platelets and megakaryocytes. An ITP diagnosis.....

EpiCast Report: Breast Cancer (HER2+, HER2-) – Epidemiology Forecast to 2025

$3,995.00
By:
, Published: Dec-2016

Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that have grown beyond the ducts or lobules of the breast and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Invasive breast cancer in this analysis is defined as ICD-10 codes C50.0–50.9, while non-invasive DCIS breast cancer is defined as ICD-10 code D05.1; both types of breast c.....

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 – Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

$4,995.00
By:
, Published: Dec-2016

Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of death worldwide, early diagnosis of the condition is crucial to improve health outcomes. Hypertension is the key risk factor for stroke; according to the National Stroke .....

EpiCast Report: Dyslipidemia – Epidemiology Forecast to 2025

$3,995.00
By:
, Published: Dec-2016

Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascular disease (CVD), and the burden of morbidity, mortality, and medical costs arising from dyslipidemia is substantial

The clinical diagnostic criteria for dyslipidemia and serum lipid abnormalities vary across countries and depend on the disease treatment and management guidelines that are followed .....

EpiCast Report: Ovarian Cancer – Epidemiology Forecast to 2025

$3,995.00
By:
, Published: Dec-2016

Ovarian cancer (OC; International Classification of Diseases, Revision 10 [ICD-10] code: C56) and cancer of the fallopian tubes and other uterine adnexa (ICD-10: C57) are leading causes of cancer mortality in women. Cancer of the ovary, fallopian tubes, and other uterine adnexa are collectively referred to as OC throughout this report. In the US, the American Cancer Society reports that OC accounts for more deaths than any other cancer of the .....

EpiCast Report: Non-Alcoholic Steatohepatitis – Epidemiology Forecast to 2025

$3,995.00
By:
, Published: Dec-2016

Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage. Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no symptoms, and most people affected with the disease feel healthy and are unaware they have a problem.

GlobalData epidemiologist.....

Partnerships, Licensing, Investments and M&A Deals and Trends for October 2016 in Pharmaceuticals

$1,000.00
By:
, Published: Dec-2016

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for October 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equ.....

Dermatology Therapeutics Drug Development Pipeline Review, 2016

$3,995.00
By:
, Published: Dec-2016

Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition. For the past decades, the majority of the dermatology market has remained saturated with established and generic products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements i.....

EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2025

$3,995.00
By:
, Published: Dec-2016

Bladder cancer is a commonly diagnosed cancer and causes significant numbers of cancer deaths worldwide. The major risk factors for bladder cancer are exposure to smoking and occupational risk factors such as exposure to aromatic amines. These risk factors are more prevalent among men, which makes the disease significantly more common in men than women. The majority of bladder cancer cases are among older individuals, with the median age at di.....

Global Cancer Immunotherapies Market to 2022 – Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market

$4,995.00
By:
, Published: Dec-2016

Cancer is a group of diseases characterized by abnormal cell growth. It is a multi-step process, as a single mutation is almost certainly insufficient to cause a cell to become malignant. A number of cellular processes must be deregulated to allow cells to proliferate uncontrollably while evading apoptosis. Initially, key cell growth, proliferative and pro-apoptotic signaling pathways are deregulated in most cancers. These signaling pathways e.....

Frontier Pharma: Hepatitis C – Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

$6,995.00
By:
, Published: Dec-2016

Hepatitis C is a blood-borne viral infection characterized by chronic inflammation of the liver. Although patients may be asymptomatic for a number of years or decades, chronic HCV infection can lead to liver fibrosis (formation of scar tissue) and ultimately liver cirrhosis, in which permanent fibrotic scar tissue replaces healthy liver cells. In severe cases, cirrhosis may lead to liver failure and death. In addition, hepatitis C patients ar.....

Big Data: Embracing Data to Transform Healthcare and Pharma Commercial Strategy – Featuring Expert Panel Views from Industry Survey 2016

$2,995.00
By:
, Published: Dec-2016

GBI Research’s latest report Big Data: Embracing Data to Transform Healthcare and Pharma Commercial Strategy – Featuring Expert Panel Views from Industry Survey 2016 provides a comprehensive analysis of the Big Data landscape. GBI Research conducted an extensive industry survey of 73 experts from the pharmaceutical and healthcare industries – including both organizations that already utilize Big Data.....

Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2016

$2,000.00
By:
, Published: Dec-2016
Global Markets Direct’s, ‘Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2016’, provides an overview of the Exocrine Pancreatic Insufficiency pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Exocrine Pancreatic Insufficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report .....

Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016

$2,000.00
By:
, Published: Dec-2016
Global Markets Direct’s, ‘Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016’, provides an overview of the Pseudomonas aeruginosa Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report .....

Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H2 2016

$2,000.00
By:
, Published: Dec-2016
Global Markets Direct’s, ‘Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H2 2016’, provides an overview of the Globoid Cell Leukodystrophy (Krabbe Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (Ro.....